CHEK1 and small cell lung carcinoma: Moreover, CHK1 inhibitors, such as LY2606368 (prexasertib), have demonstrated significant activity in preclinical SCLC models, particularly when combined with agents such as cisplatin or PARP inhibitors, enhancing DNA damage and apoptosis.